• Doctor Radio Feature Interview with Dr. Feldman and Ted Harada

Doctor Radio host, NYU’s Dr. Nieca Goldberg, interviews NSI-566/ALS principal investigator Dr. Eva Feldman and Phase I patient Ted Harada in this expansive one-hour segment on ALS that brought calls from present and past ALS caregivers from around the country. The feature includes firsthand insights on Neuralstem’s completed and upcoming ALS trials. Notably Dr. Feldman said that, while the trial is just entering Phase II, that the team believes the results are extremely promising, and pointed out the heretofore dearth of ALS treatments for this chronic, progressive, neurodegenerative disease since Lou Gehrig was diagnosed in the 1930’s. Ted shared poignant and heartfelt “new lease on life” memories after his initial NSI-566 treatment - and a call to action as well as support for the ALS community from his spot on Capitol Hill, where he was meeting with senators and representatives on National ALS Advocacy Day.

Podcast on demand available to SiriusXM Subscribers: Doctor Radio, Women's Health, 5/9/13 10:00-11:00 a.m. ET
http://www.siriusxm.com/ondemand

5/12 and 5/13 Rebroadcast: Women's Health: Sun, 5/12, 2:00 a.m. ET (Sat., 5/11, 11:00 p.m. PT) and Mon, 5/13, 4:00 a.m. ET
http://www.siriusxm.com/freetrial

• Neuralstem: Anticipating More Efficacy Data From ALS Trial and Update On New Clinical Trials

Former biotech/pharma analyst and former Director of Research at Smith Barney and Hambrecht and Quist, Larry Smith, pens an expansive article and analysis of Neuralstem’s NSI-566/ALS Phase I trial and provides an overview of the company’s upcoming clinical trials for ALS and other conditions.

View Article

• Ted Harada: His ALS Miracle Continues to Amaze

“Today, Harada told me nearly all the improvement that happened after his last injection is still evident,” writes Tom Henderson in this thoughtful article on NSI-566/ALS patient Ted Harada who shared thoughts about the upcoming Phase II trial and his happily cane-free health status. According to Ted, “It’s clear from the data that the injections reversed my symptoms and slowed down the progression of the disease. I’ve received a blessing. I almost forget I have ALS.”

View Article

• Drug might treat depression, brain damage in athletes

President and CEO Richard Garr is quoted in this comprehensive story on Neuralstem’s NSI-189/traumatic brain injury initiative with the National Football League Alumni Association.

View Article

• Possible Brain Drug Test: NFL group, company hope to conduct new trial

In this trend segment on potential treatments for traumatic brain injury and PTSD, Jenna Lee interviews FOX News contributor, neurologist Dr. Matthew Fink, about Neuralstem’s new NSI-189/TBI initiative with the NFLAA.

View Segment